(Reuters) -The U.S. Food and Drug Administration on Friday approved Krystal Biotech Inc's first-of-its kind topical gene therapy for patients with a genetic skin disorder, sending its shares up 7% in ...
A rare skin disorder that leads to fragile skin susceptible to frequent wounds and blisters now has its first FDA-approved therapy, a topically applied gel that facilitates healing. The Krystal ...
The U.S. Food and Drug Administration (FDA) on Friday approved Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Dupixent (dupilumab) for adult patients with bullous pemphigoid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback